Pedestrians walk in front of the U.S. Supreme Court February 29, 2024 in Washington, DC.
Robert Nickelsberg | Getty Images
The Supreme Court on Tuesday tackles whether to take care of widely available access to the abortion pill mifepristone because it weighs a high-stakes challenge to the Food and Drug Administration’s drug approval process.
The court, which has a 6-3 conservative majority, hears oral arguments on the Biden administration’s appeal of lower court rulings that restricted access to the pill, including its availability by mail.
Mifepristone is used as a part of a two-drug FDA-approved regimen for the majority of abortions nationwide.
The case is a significant test for the conservative-majority court, which in 2022 overturned Roe v. Wade, the landmark ruling that established a lady’s constitutional right to finish her pregnancy.
A bunch of anti-abortion doctors represented by Alliance Defending Freedom, a conservative Christian legal group, is leading the legal challenge, claiming that the FDA did not adequately evaluate the drug’s safety risks.
The FDA has the backing of the pharmaceutical industry, which has warned that any second-guessing of the approval process by untrained federal judges could cause chaos and deter innovation.
Danco, which makes the brand version of the pill, Mifeprex, is arguing alongside the FDA within the oral argument.
The oral argument comes almost a 12 months after Texas-based U.S. District Judge Matthew Kacsmaryk issued a sweeping ruling that completely invalidated the FDA’s approval of the pill, resulting in panic amongst abortion rights activists that it might be banned altogether.
The Supreme Court last April put that ruling on hold, meaning the pill stays widely available for now.
The Recent Orleans-based fifth U.S. Circuit Court of Appeals in August then narrowed Kacsmaryk’s decision on appeal, but left in place his ruling finding that the FDA’s move to lift restrictions starting in 2016 was illegal.
Each side appealed to the Supreme Court. The court in December took up the Biden administration’s appeal in defense of the later FDA decisions, nevertheless it opted against hearing the challenge to the unique approval of mifepristone in 2000. That issue is subsequently not before the justices.
The court will as an alternative give attention to the later FDA motion, including the initial 2021 decision that made it available by mail, which was finalized last 12 months.
The court may even consider decisions in 2016 to increase the window wherein mifepristone may very well be used to terminate pregnancies from seven weeks’ gestation to 10 weeks and reduce the variety of in-person visits for patients from three to at least one. In one other 2016 move, the FDA altered the dosing regimen, finding that a lower dose of mifepristone was sufficient.
A method the court could eliminate the case can be to conclude that the challengers don’t have legal standing to bring their lawsuit, which might mean the justices wouldn’t wrestle with the query of FDA approval. If the court takes that route, it would go away the door open to a future case.
In court papers, the FDA has argued that the doctors and others who filed the lawsuit don’t have legal standing because they can’t show any injury that will be traced to the drug approval process.
The doctors don’t prescribe mifepristone, but they argue that they’re injured because they may very well be required to treat patients who’ve taken the pill and have serious uncomfortable side effects. As they oppose abortion, any actions they’re forced to take to assist a lady complete the method would make them complicit, the plaintiffs argued in court papers.
The end result of the case could have sweeping practical effects if access to the drug is restricted, with many states in search of to limit abortion access within the wake of the Supreme Court’s decision to overturn Roe v. Wade.
There are 14 states where abortion is effectively banned altogether, in response to the Guttmacher Institute, a research group that backs abortion rights.
